Pelvital Stress Urinary Incontinence Training Device: P-SUIT

120 subjects with SUI will be recruited into a randomized, double-blind, sham-controlled
crossover trial. Subjects will be allocated in a 1:1 ratio (60 per arm) to either the control
arm (PFMT) or the treatment arm (PFMT in conjunction with the Pelvital therapy). Subjects
will conduct their respective therapy five minutes a day over the course of six weeks. At
weeks two, four and six, the subjects will conduct bi-weekly check-ups. After six weeks, all
patients in the control arm will have the option to cross over into the treatment arm if no
improvement in symptoms has been shown.

Inclusion Criteria:

1. Female gender,

2. Ages 18-75,

3. Clinical diagnosis of stress urinary incontinence,

4. Ability to contract the pelvic floor muscles,

5. Able to document incontinence and voiding in a diary,

6. Provision of written informed consent form,

7. Minimum of 10 grams increase at initial 24-hour pad weight test

Exclusion Criteria:

1. Diagnosed mixed or urge urinary incontinence,

2. Impaired cognitive function or neurologic conditions

3. Physical limitations that impede the patient's ability to participate (e.g., ability
to stand),

4. Acute infections or hematuria,

5. Pregnant or actively trying to conceive,

6. History of pelvic irradiation,

7. Concurrent medications with α-adrenergic antagonists or diuretics

8. Pelvic organ prolapse stage III or IV,

9. Severe urethral sphincter weakness and/or defect,

10. Suspected urethral and/or vesical fistula